Promoter hypermethylation profile of kidney cancer

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Essel DulaimiPaul Cairns

Abstract

Promoter hypermethylation is an important mechanism of inactivation of tumor suppressor genes in cancer cells. Kidney tumors are heterogeneous in their histology, genetics, and clinical behavior. To gain insight into the role of epigenetic silencing of tumor suppressor and cancer genes in kidney tumorigenesis, we determined a hypermethylation profile of kidney cancer. We examined the promoter methylation status of 10 biologically significant tumor suppressor and cancer genes in 100 kidney tumors (50 clear cell, 20 papillary, 6 chromophobe, 5 collecting duct, 5 renal cell unclassified, 7 oncocytoma, 6 transitional cell carcinomas of the renal pelvis, and 1 Wilms' tumor) by methylation-specific PCR. The hypermethylation profile was examined with regard to clinicopathological characteristics of the kidney cancer patients. Hypermethylation of one or more genes was found in 93 (93%) of 100 tumors. A total of 33% of kidney tumors had one gene, 35% two genes, 14% three genes, and 11% four or more genes hypermethylated. The frequency of hypermethylation of the 10 genes in the 100 tumor DNAs was VHL 8% (all clear cell), p16(INK4a) 10%, p14(ARF) 17%, APC 14%, MGMT 7%, GSTP1 12%, RARbeta2 12%, RASSF1A 45%, E-cadherin 11%, and Timp-3 58%. ...Continue Reading

References

Jan 25, 1991·Cell·J M Bishop
Jul 20, 1987·Journal of Molecular Biology·M Gardiner-Garden, M Frommer
Oct 1, 1982·The American Journal of Surgical Pathology·S A FuhrmanC Limas
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·J G HermanW M Linehan
Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·S A BelinskyJ G Herman
Feb 9, 1999·Human Molecular Genetics·T H HuangD E Laux
Feb 13, 1999·Nature Genetics·P A Jones, P W Laird
Jun 3, 2000·Nature Genetics·H L Klein
May 18, 2001·Nature·J Taipale, P A Beachy
Feb 28, 2002·Nature Genetics·Ian P M TomlinsonUNKNOWN Multiple Leiomyoma Consortium
Mar 14, 2002·Proceedings of the National Academy of Sciences of the United States of America·Daiya Takai, Peter A Jones
Sep 3, 2002·Cancer Cell·Charles J Sherr, Frank McCormick
Feb 6, 2003·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Feb 17, 2009·Current Oncology Reports·C Lance Cowey, W Kimryn Rathmell
Jan 24, 2007·Current Urology Reports·David A KunkleRobert G Uzzo
Dec 27, 2011·Cancer Letters·Carmen Jerónimo, Rui Henrique
Sep 18, 2010·Pathology International·Koo Han YooSung-Goo Chang
Apr 9, 2011·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·Eri AraiYae Kanai
Nov 1, 2009·Therapeutic Advances in Medical Oncology·Tanya B DorffDavid I Quinn
Feb 14, 2012·Molecular Cancer·Shahana MajidRajvir Dahiya
Sep 29, 2012·BMC Medicine·Naveen S VasudevRosamonde E Banks
Sep 8, 2010·Genome Medicine·Mark R Morris, Eamonn R Maher
Nov 10, 2013·PloS One·Ilsiya IbragimovaPaul Cairns
Dec 1, 2011·Epigenomics·Amanda M Hoffman, Paul Cairns
Dec 7, 2013·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Carolina ReyesRobert A Soslow
Jul 13, 2014·Biochemical and Biophysical Research Communications·Hiromu SuzukiMasahiro Kai
Dec 18, 2004·Critical Reviews in Clinical Laboratory Sciences·Mukesh VermaSudhir Srivastava
Jun 1, 2014·Critical Reviews in Clinical Laboratory Sciences·Dimo DietrichGlen Kristiansen
Feb 3, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Emma Andersson EvelönnGöran Roos
Jul 19, 2011·Hematology/oncology Clinics of North America·Marc C SmaldoneNaomi B Haas
Jan 12, 2008·Biochimica Et Biophysica Acta·Marcella M L BaldewijnsManon van Engeland
Dec 2, 2006·Urologic Oncology·Robert W Veltri, Danil V Makarov
Feb 3, 2006·International Journal of Cancer. Journal International Du Cancer·Eri AraiSetsuo Hirohashi
Sep 10, 2005·International Journal of Cancer. Journal International Du Cancer·Daisuke YamadaYoshinori Murakami
Oct 8, 2008·Annals of the New York Academy of Sciences·Ying-Hsiu SuTimothy M Block
Mar 8, 2008·BJU International·Antonio Rubio-Del-CampoJulio Escribano
May 6, 2011·International Journal of Cancer. Journal International Du Cancer·Masayoshi NagataYoshinori Murakami
Jun 18, 2010·BJU International·Jörg EllingerPatrick J Bastian
Dec 5, 2009·Birth Defects Research. Part C, Embryo Today : Reviews·Hoi-Hung CheungWai-Yee Chan
Mar 24, 2016·Cell Biochemistry and Function·Amr Rafat Elhamamsy
Jul 25, 2006·Critical Reviews in Oncology/hematology·James M G Larkin, Tim Eisen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Mark L GonzalgoChristian P Pavlovich
Proceedings of the National Academy of Sciences of the United States of America
James G HermanW M Linehan
International Journal of Cancer. Journal International Du Cancer
J H YoonG P Pfeifer
Proceedings of the National Academy of Sciences of the United States of America
K DreijerinkE R Zabarovsky
© 2022 Meta ULC. All rights reserved